Biotech/Health
•2 min read
Zealand and Roche’s Next-Gen Obesity Drug Hits 9% Weight Loss With Minimal GI Side Effects
Zubiqo Take
“The 9.2% weight loss won't dethrone Lilly or Novo outright, but that 1.9% GI dropout rate is a massive commercial weapon for the millions of patients who can't stomach the current GLP-1 side effects.”
BullishMag 7
Reuters